Abstract
BackgroundPrevalence of hepatitis C virus infection in patients with renal diseases is higher compared to the general population. FDA has approved ombitasvir/paritaprevir/ ritonavir for the treatment of patients with severe renal disease. This study aimed to evaluate the efficacy and safety of ombitasvir/paritaprevir/ritonavir with or without ribavirin in treatment of chronic hepatitis C Egyptian hemodialysis patients to compare it with the same treatment result in chronic hepatitis C Egyptian patients with normal renal functions. This case-control study was conducted on one hundred patients with confirmed diagnosis of HCV-positive infection at the Center of National Committee for Control of Viral Hepatitis [NCCVH] at Ain Shams University Hospital. Patients were divided into two groups: group I (control group) with 50 chronic hepatitis C virus patients with normal renal functions and group II (Case Group) with 50 chronic hepatitis C virus hemodialysis patients.Results95.1% of prevalent hemodialysis patients achieved sustained virological response (SVR), while 100% of patients with normal kidney functions achieved sustained virological response. Most common side effects were hemoglobin drop, gastrointestinal disturbance, severe fatigue, and itching.ConclusionOmbitasvir, paritaprevir, and ritonavir are considered a safe and effective in treatment in HCV infection in patients on regular hemodialysis as in chronic hepatitis C virus infection patients with normal kidney functions.
Highlights
Prevalence of hepatitis C virus infection in patients with renal diseases is higher compared to the general population
Three direct-acting antiviral (3D) regimen is an alloral interferon-free combination of the protease inhibitor paritaprevir co-formulated with ritonavir as a systemic PK enhancer and the nonstructural protein 5A (NS5A) inhibitor ombitasvir [4]
All patients with chronic hepatitis C were treated with ombitasvir/paritaprevir/ritonavir with or without ribavirin during the period between May 2018 and December 2018
Summary
Prevalence of hepatitis C virus infection in patients with renal diseases is higher compared to the general population. This study aimed to evaluate the efficacy and safety of ombitasvir/paritaprevir/ritonavir with or without ribavirin in treatment of chronic hepatitis C Egyptian hemodialysis patients to compare it with the same treatment result in chronic hepatitis C Egyptian patients with normal renal functions This case-control study was conducted on one hundred patients with confirmed diagnosis of HCV-positive infection at the Center of National Committee for Control of Viral Hepatitis [NCCVH] at Ain Shams University Hospital. The FDA has endorsed ombitasvir/paritaprevir/ ritonavir (OBV/PTV/ RITONA) for treatment of patients with severe renal disease. Metabolism of these compounds is mediated mainly by the liver. Treatment with OBV/PTV/RITONA ± RBV is currently approved for patients infected with HCV, based on the results of several clinical trials in which sustained virological response (SVR) rates at week 12 (SVR12) reached 95– 100% [5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
